Sun Pharma Advanced Research Co 21st AGM scheduled on Aug 10
NiveshIQ
NSE: SPARC · Pharma
Sun Pharma Advanced Research Company Ltd.
₹196.01▼ ₹0.90 (-0.46%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on SPARC. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Sun Pharma Advanced Research Company Ltd.
Sun Pharma Advanced Research Company Limited (SPARC) is a research-driven pharmaceutical company that develops innovative products for various therapeutic areas, including neurology, oncology, and ophthalmology. The company's key revenue drivers include its pipeline of novel formulations, such as Sezaby for neonatal seizures and SPARC-121 for Alopecia Areata. Recently, SPARC reported a loss of Rs. 20.78 crore in Q1FY27, with revenue jumping multi-fold year-over-year, resulting in a narrowed loss. The company has also become debt-free after selling assets worth ₹1,600 crore, providing a significant relief to its balance sheet. SPARC's competitive position is supported by its strong research and development capabilities, with a focus on developing first-in-class or best-in-class products. Lo
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹76.00 Cr -68.20% | ₹71.77 Cr -5.60% | ₹1,879 Cr +2518.30% |
| EBITDA Margin | -528.95% | -447.75% | 85.66% |
| Net Profit | ₹1,566 Cr | ||
| EPS | ₹-11.93 | ₹-10.55 | ₹47.86 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Geojit Highlights Syrma SGS, SPARC, Aster DM Technical Setup
Aster DM, SPARC among 3 stocks looking strong on tech charts, says Geojit
🔒
+ 3 more stories about Sun Pharma Advanced Research Company Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹40 Cr, PAT ₹-21 Cr, EPS ₹-0.64, EBITDA margin -25.9%. Growth context: revenue QoQ -97.8%, PAT QoQ -101.2%.
Recent corporate activity highlights product launches, approvals, and therapy-mix improvement and R&D investments and te...
FY26 (last completed FY): revenue ₹1, 879 Cr, PAT ₹1, 566 Cr, EBITDA margin 85.7%, EPS ₹47.86. Year-on-year: revenue YoY...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for SPARC
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track SPARC alongside your other holdings
Unlock full SPARC research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Sun Pharma Advanced Research Company Ltd.?
NiveshIQ detects active intelligence signals for Sun Pharma Advanced Research Company Ltd. (SPARC) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Sun Pharma Advanced Research Company Ltd.?
Sun Pharma Advanced Research Company Ltd. operates in the Pharma sector with a market capitalisation of ₹562,071.4L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.